干扰素治疗肿瘤相关的信号通路及临床应用

doi:10.3760/cma.j.cn371439-20191230-00037

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (6): 364-367.doi: 10.3760/cma.j.cn371439-20191230-00037

干扰素治疗肿瘤相关的信号通路及临床应用

李钰祥, 王新文()

军事口腔医学国家重点实验室口腔疾病国家临床医学研究中心陕西省口腔疾病临床医学研究中心空军军医大学第三附属医院黏膜科,西安 710000

收稿日期:2019-12-30 修回日期:2020-01-07 出版日期:2020-06-08 发布日期:2020-07-22
通讯作者: 王新文 E-mail:landw211@163.com
基金资助:
国家自然科学基金(81371154);军事口腔医学国家重点实验室课题(2018ZB01)

Interferon-related signaling pathways and clinical application in tumor therapy

Li Yuxiang, Wang Xinwen()

State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases, Department of Oral Medicine, School of Stomatology, Fourth Military Medical University, Xi'an 710000, China

Received:2019-12-30 Revised:2020-01-07 Online:2020-06-08 Published:2020-07-22
Contact: Wang Xinwen E-mail:landw211@163.com
Supported by:
National Natural Science Foundation of China(81371154);State Key Laboratory of Military Stomatology(2018ZB01)

摘要/Abstract

摘要：

Ⅰ、Ⅱ、Ⅲ型干扰素虽都具有抗肿瘤潜能,但作用机制和临床疗效有所不同。与干扰素治疗肿瘤相关的信号通路主要包括JAK-STAT、PI3K/AKT/mTOR、MAPK、NF-κB、c-Abl等。目前Ⅰ型干扰素临床应用最广,疗效最明确;Ⅱ型干扰素因存在严重的不良反应且可能在诱导癌变过程中发挥作用,对其是否可以用于抗肿瘤治疗存在较大争议;Ⅲ型干扰素虽在生物学功能上兼备了Ⅰ、Ⅱ型干扰素的优良特点,但其对抗肿瘤的药用价值还有待进一步评估。

关键词: 干扰素类, 肿瘤, 信号通路, 临床应用

Abstract:

Type Ⅰ, Ⅱ, Ⅲ interferons have anti-tumor potential, but the mechanism of action and clinical effect are different. Signaling pathways associated with interferon-treated tumors mainly include JAK-STAT, PI3K/AKT/mTOR, MAPK, NF-κB, c-Abl, etc. Type Ⅰ interferon has the widest clinical application and the most definite curative effect at present. Because of its serious adverse reaction and possible role in the process of cancer induction, type Ⅱ interferon has a great controversy on whether it can be used in anti-tumor therapy. The biological function of type Ⅲ interferon has good characteristics of type Ⅰ and Ⅱ interferon, but its anti-tumor medicinal value needs to be further evaluated.

Key words: Interferons, Neoplasms, Signal pathway, Clinical trial

李钰祥, 王新文. 干扰素治疗肿瘤相关的信号通路及临床应用[J]. 国际肿瘤学杂志, 2020, 47(6): 364-367.

Li Yuxiang, Wang Xinwen. Interferon-related signaling pathways and clinical application in tumor therapy[J]. Journal of International Oncology, 2020, 47(6): 364-367.

参考文献 27

[1]	Rentiya ZS, Wells M, Bae J, et al. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations[J]. Graefes Arch Clin Exp Ophthalmo, 2019,257(3):447-452. DOI: 10.1007/s00417-018-04209-7. doi: 10.1007/s00417-018-04209-7
[2]	Sceneay J, Goreczny GJ, Wilson K, et al. Interferon signaling is diminished with age and is associated with Immune checkpoint blockade efficacy in triple-negative breast cance[J]. Cancer Discov, 2019,9(9):1208-1227. DOI: 10.1158/2159-8290.CD-18-1454. doi: 10.1158/2159-8290.CD-18-1454 pmid: 31217296
[3]	Lasfar A, Gogas H, Zloza A, et al. IFN-λ cancer immunotherapy: new kid on the block[J]. Immunotherapy, 2016,8(8):877-888. DOI: 10.2217/imt-2015-0021. doi: 10.2217/imt-2015-0021 pmid: 27381684
[4]	Mitchell S, Mercado EL, Adelaja A, et al. An NFκB activity calculator to delineate signaling crosstalk: type Ⅰ and Ⅱ interferons enhance NFκB via distinct mechanisms[J]. Front Immunol, 2019,10:1425. DOI: 10.3389/fimmu.2019.01425. doi: 10.3389/fimmu.2019.01425 pmid: 31293585
[5]	Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion[J]. Int J Mol Sci, 2017, 19(1). pii: E89. DOI: 10.3390/ijms19010089. pmid: 29351251
[6]	Ni L, Lu J. Interferon gamma in cancer immunotherapy[J]. Cancer Med, 2018,7(9):4509-4516. DOI: 10.1002/cam4.1700. doi: 10.1002/cam4.1700 pmid: 30039553
[7]	O'Brien TR, Young HA, Donnelly RP, et al. Meeting overview: interferon lambda-disease impact and therapeutic potential[J]. J Interferon Cytokine Res, 2019,39(10):586-591. DOI: 10.1089/jir.2019.0018. doi: 10.1089/jir.2019.0018 pmid: 30998425
[8]	Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type Ⅰ and type Ⅲ interferons[J]. Immunity, 2019,50(4):907-923. DOI: 10.1016/j.immuni.2019.03.025. doi: 10.1016/j.immuni.2019.03.025 pmid: 30995506
[9]	Zhao Q, Cheng W, Xi Y, et al. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis[J]. Mol Immunol, 2018,93:20-30. DOI: 10.1016/j.molimm.2017.11.002. doi: 10.1016/j.molimm.2017.11.002 pmid: 29127843
[10]	Bhat MY, Solanki HS, Advani J, et al. Comprehensive network map of interferon gamma signaling[J]. J Cell Commun Signal, 2018,12(4):745-751. DOI: 10.1007/s12079-018-0486-y. doi: 10.1007/s12079-018-0486-y pmid: 30191398
[11]	Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins[J]. J Interferon Cytokine Res, 2011,31(1):33-40. DOI: 10.1089/jir.2010.0100. doi: 10.1089/jir.2010.0100 pmid: 21166594
[12]	Yeh YH, Hsiao HF, Yeh YC, et al. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway[J]. J Exp Clin Cancer Res, 2018,37(1):70. DOI: 10.1186/s13046-018-0730-6. doi: 10.1186/s13046-018-0730-6 pmid: 29587825
[13]	Al-Attar R, Childers CL, Nguyen VC, et al. Differential protein phosphorylation is responsible for hypoxia-induced regulation of the Akt/mTOR pathway in naked mole rats[J]. Comp Biochem Physiol A Mol Integr Physiol, 2020,242:110653. DOI: 10.1016/j.cbpa.2020.110653. doi: 10.1016/j.cbpa.2020.110653 pmid: 31926299
[14]	Ma RJ, Tan YQ, Zhou G, et al. Aberrant IGF1-PI3K/AKT/MTOR signaling pathway regulates the local immunity of oral lichen planus[J]. Immunobiology, 2019,224(3):455-461. DOI: 10.1016/j.imbio.2019.01.004. doi: 10.1016/j.imbio.2019.01.004 pmid: 30773287
[15]	梁木林, 党红星, 鲁雪, 等. 抑制mTOR信号通路对幼鼠肺损伤时p-AKT1分子的影响及意义[J]. 中国病理生理杂志, 2019,35(3):506-514. DOI: 10.3969/j.issn.1000-4718.2019.03.021.
[16]	Wang H, Wang J, Shi X, et al. Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-γ and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway[J]. J BUON, 2017,22(6):1517-1524. pmid: 29332347
[17]	Valledor AF, Sánchez-Tilló E, Arpa L, et al. Selective roles of MAPKs during the macrophage response to IFN-gamma[J]. J Immunol, 2008,180(7):4523-4529. DOI: 10.4049/jimmunol.180.7.4523. doi: 10.4049/jimmunol.180.7.4523 pmid: 18354174
[18]	Truong AD, Hong Y, Hoang CT, et al. Chicken IL-26 regulates immune responses through the JAK/STAT and NF-κB signaling pathways[J]. Dev Comp Immunol, 2017,73:10-20. DOI: 10.1016/j.dci.2017.03.001. doi: 10.1016/j.dci.2017.03.001 pmid: 28259699
[19]	Ning L, Huang X, Xu Y, et al. Boosting of hepatitis B virus-specific T cell responses after pegylated-interferon-alpha-2a therapy for hepatitis B e antigen-positive pediatric patients[J]. J Interferon Cytokine Res, 2019,39(12):740-751. DOI: 10.1089/jir.2019.0042. doi: 10.1089/jir.2019.0042 pmid: 31329012
[20]	Suzuki T, Sakata K, Mizuno N, et al. Different involvement of the MAPK family in inflammatory regulation in human pulmonary microvascular endothelial cells stimulated with LPS and IFN-gamma[J]. Immunobiology, 2018,223(12):777-785. DOI: 10.1016/j.imbio.2018.08.003. doi: 10.1016/j.imbio.2018.08.003 pmid: 30115376
[21]	Suarez-Kelly LP, Levine KM, Olencki TE, et al. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma[J]. Cancer Immunol Immunother, 2019,68(4):619-629. DOI: 10.1007/s00262-019-02308-w. doi: 10.1007/s00262-019-02308-w pmid: 30725205
[22]	Lowenstein A, Fainboim H, Reyes A, et al. Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: a prospective study[J]. Endocrinol Diabetes Nutr, 2019. pii: S2530-0164(19)30144-2. DOI: 10.1016/j.endinu.2019.04.012. doi: 10.1016/j.endinu.2020.01.006 pmid: 32499203
[23]	Ding GQ, Yu YL, Shen ZJ, et al. Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells[J]. J Zhejiang Univ Sci B, 2012,13(5):335-341. DOI: 10.1631/jzus.B1100366. doi: 10.1631/jzus.B1100366 pmid: 22556170
[24]	Liu Y, Liu G, Liu Q, et al. The cellular character of liquefaction degeneration in oral lichen planus and the role of interferon gamma[J]. J Oral Pathol Med, 2017,46(10):1015-1022. DOI: 10.1111/jop.12595. doi: 10.1111/jop.12595 pmid: 28556960
[25]	Lv N, Gao Y, Guan H, et al. Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines[J]. Oncol Lett, 2015,10(4):2591-2597. DOI: 10.3892/ol.2015.3518. doi: 10.3892/ol.2015.3518 pmid: 26622895
[26]	Gao D, Yu X, Zhang B, et al. Role of autophagy in inhibiting the proliferation of A549 cells by type Ⅲ interferon[J]. Cell Biol Int, 2019,43(6):605-612. DOI: 10.1002/cbin.11132. doi: 10.1002/cbin.11132 pmid: 30958598
[27]	Choobin H, Bamdad T, Soleimanjahi H, et al. Antitumor effect of mIFN-lambda3 in C57BL/6 mice model for papilloma tumors[J]. Mol Biol (Mosk), 2015,49(5):777-784. DOI: 10.7868/S0026898415050067.

干扰素治疗肿瘤相关的信号通路及临床应用

Interferon-related signaling pathways and clinical application in tumor therapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.